Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-05-10
2005-05-10
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800, C514S016700, C514S017400, C514S018700, C514S019300
Reexamination Certificate
active
06890904
ABSTRACT:
A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
REFERENCES:
patent: 4318904 (1982-03-01), Shaw et al.
patent: 4443609 (1984-04-01), Oude Alink et al.
patent: 4499082 (1985-02-01), Shenvi et al.
patent: 4582821 (1986-04-01), Kettner et al.
patent: 4636492 (1987-01-01), Kettner et al.
patent: 4644055 (1987-02-01), Kettner et al.
patent: 4652552 (1987-03-01), Kettner et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 4963655 (1990-10-01), Kinder et al.
patent: 5093477 (1992-03-01), Mölling et al.
patent: 5187157 (1993-02-01), Kettner et al.
patent: 5215926 (1993-06-01), Etchells, III et al.
patent: 5242904 (1993-09-01), Kettner et al.
patent: 5250720 (1993-10-01), Kettner et al.
patent: 5288707 (1994-02-01), Metternich
patent: 5296604 (1994-03-01), Hanko et al.
patent: 5329028 (1994-07-01), Ashkenazi et al.
patent: 5378624 (1995-01-01), Berenson et al.
patent: 5384410 (1995-01-01), Kettner
patent: 5444049 (1995-08-01), de Nanteuil et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5506130 (1996-04-01), Peterson et al.
patent: 5527923 (1996-06-01), Klingler et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5587299 (1996-12-01), Rettig et al.
patent: 5635386 (1997-06-01), Palsson et al.
patent: 5635387 (1997-06-01), Fei et al.
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5646043 (1997-07-01), Emerson et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5767242 (1998-06-01), Zimmermann et al.
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 5854221 (1998-12-01), Cao et al.
patent: 5965373 (1999-10-01), Zimmermann et al.
patent: 5965532 (1999-10-01), Bachovchin
patent: 6040145 (2000-03-01), Huber et al.
patent: 6090786 (2000-07-01), Augustyns et al.
patent: 6265551 (2001-07-01), Duke-Cohan et al.
patent: 6503882 (2003-01-01), Huber et al.
patent: 20020034789 (2002-03-01), Zimmermann et al.
patent: 20030130199 (2003-07-01), von Hoersten et al.
patent: 729369 (2001-02-01), None
patent: 158109 (1982-12-01), None
patent: 270382 (1989-07-01), None
patent: 296075 (1991-11-01), None
patent: 0356223 (1990-02-01), None
patent: 0371467 (1990-06-01), None
patent: 0471651 (1992-02-01), None
patent: 0481311 (1992-04-01), None
patent: 0615978 (1994-09-01), None
patent: 0420913 (1995-11-01), None
patent: 0688788 (1995-12-01), None
patent: 335543 (2001-03-01), None
patent: WO8903223 (1989-04-01), None
patent: WO9116339 (1991-10-01), None
patent: WO9117767 (1991-11-01), None
patent: WO9212140 (1992-07-01), None
patent: WO9217490 (1992-10-01), None
patent: WO9302057 (1993-02-01), None
patent: WO9305011 (1993-03-01), None
patent: WO9308259 (1993-04-01), None
patent: WO9310127 (1993-05-01), None
patent: WO9316102 (1993-08-01), None
patent: WO9403055 (1994-02-01), None
patent: WO9409132 (1994-04-01), None
patent: WO9420526 (1994-09-01), None
patent: WO9425873 (1994-11-01), None
patent: WO9428915 (1994-12-01), None
patent: WO9429335 (1994-12-01), None
patent: WO9511689 (1995-05-01), None
patent: WO9512618 (1995-05-01), None
patent: WO 9515309 (1995-06-01), None
patent: WO9529190 (1995-11-01), None
patent: WO 9529233 (1995-11-01), None
patent: WO9529691 (1995-11-01), None
patent: WO9534538 (1995-12-01), None
patent: WO9640263 (1996-12-01), None
patent: WO9640858 (1996-12-01), None
patent: WO 9734927 (1997-09-01), None
patent: WO9800439 (1998-01-01), None
patent: WO 9825644 (1998-06-01), None
patent: WO9850046 (1998-11-01), None
patent: WO9850066 (1998-11-01), None
patent: WO9919864 (1999-04-01), None
patent: WO 9947152 (1999-09-01), None
patent: WO 9956753 (1999-11-01), None
patent: WO 9962914 (1999-12-01), None
patent: WO 0010549 (2000-03-01), None
Thompson, R.C.., “Peptide Aldehydes:Potent Inhibitors of Serine and Cysteine Proteases”Methods In Enzymology,vol. XLVI, Chapter 19 pp. 220-225 (not dated).
Cordes, E., et al., “Transition States For Hydrolysis Of Acetals, Ketals Glycosides, And Glycosylamines”, Chapter 11, pp. 429-465 (not dated).
Baugh, R., et al., “Role and Potential Therapeutic Value of Proteinase Inhibitors in Tissue Destruction”Proteinases And Tumor Invasion,(1980), 165:157-179.
Bodanszky, M., “Principles Of Peptide Synthesis”,Springer-Verlag,(1984), vol. 16.
Bodanszky, M., “The Practice Of Peptide Synthesis”,Springer-Verlag,(1984), vol. 21.
Matteson, D., et al., “Synthesis And Properties Of Pinanediol α-Amido Boronic Esters”Organometallics,(1984), 3:1284-1288.
Powers, J.C. and Bengali, Z.H., “Elastase Inhibitors for Treatment of Emphysema”NHLBI Workshop Summary US Dept. of Health and Human Services,(1985), 1097-1100.
Yoshimoto, T., et al., “Comparison Of Inhibitory Effects Of Prolinal-Containing Peptide Derivates On Prolyl . . . ”,J. Biochemistry(1985), 98:975-979.
Kettner, C.A., et al., “Kinetic Properties Of The Binding Of Alpha-Lytic Protease To Peptide Boronic Acids”,Biochemistry,(1988), 27:7682-7688.
Tam, J.P., “Synthetic Peptide Vaccine Design: Synthesis And Properties Of A High-Density Multiple Antigenic Peptide System”,Proc Natl Acad Sci U S A ,(1988), 85:5409-5413.
Bailey, P.D., “An Introduction To Peptide Chemistry”,Wiley Publishers,(1990), 1-81.
Kettner, C.A. and Shenvi, A.B., “Peptide boronic acid inhibitors of trypsin-like proteases, their preparation and use as anticoagulants and inlammation Inhibitors”Chemical Abstracts,(1990), 112:80 (91790c).
Bachovchin, W.W., et al., “Inhibition Of Igal Proteinases From Neisseria Gonorrhoeae And Hemophilus Hemophilus Influenzae By Peptide Prolyl Boronic Acids”,J Biol Chem,(1990), 265: 3738-3743.
Kinder D.H., et al., “Analogues Of Carbamyl Aspartate As Inhibitors Of Dihydroorotase: Preparation Of Boronic Acid Transition-State Analogues And A Zinc Chelator Carbamylhomocysteine”,J Med Chem,(1990), 33:819-823.
Flentke, G.R., et al., “Inhibition Of Dipeptidyl Aminopeptidase Iv (Dp-Iv) By Xaa-Boropro Dipeptides And Use Of These Inhibitors To Examine The Role Of Dp-Iv In T-Cel Function”Proc Natl Acad Sci U S A,(1991), 88:1556-1559.
Schon, E., et al., “Dipeptidyl Peptidase IV In The Immune System. Effects Of Specific Enzyme Inhibitors On On Activity Of Dipeptidase IV And Proliferation Of Human Lymphocytes”,Biological Chemistry Hoppe Seyler372:305-311 (1991).
Kubota, T., et al., “Involvement Of Dipeptidyl Peptidase Iv In An In Vivo Immune Response”,Clin Exp Immunol,(1992), 89:192-197.
Gutheil, W.G., et al., “Separation Of L-Pro-DL-Boropro Into Its Component Diastereomers And Kinetic Analysis Of Their Inhibition Of Dipeptidyl Peptidase IV. A New Method For The Analysis Of Slow, Tight-Binding Inhibitition”,Biochemistry,(1993), 32:8723-8731.
Kelly, T.A., et al., “Immunosuppressive Boronic Acid Dipeptides: Correlation Between Conformation And Activity”,J Am Chem Soc,(1993), 115:12637-12638.
Songyang, Z., et al., “SH2 Domains Recognize Specific Phosphopeptide Sequences”,Cell,(1993), 72:767-778.
Subramanyama, M., et al. , “Mechanism Of Hiv-1 Tat Induced Inhibition Of Antigen-Specific T Cell Responsiveness”,J Immunol,(1993), 150(6):2544-2553.
Demuth, H.U., et al., “Design Of (Omega-N-(O-Acyl)Hydroxy Amid) Aminodicarboxylic Acid Pyrrolidides As Potent Inhibitors Of Proline-Specific Peptidases”,FEBS Lett,(1993), 320:23-27.
Janeway, C., et al., “Immunobiology—The Immune System In Health And Disease”,Current Biology LTD,(1994), Chapter 12, pp 1-35.
Brady, L., and Doson, G., “Reflections On A Peptide”,Nature,(1994), 368:692-693.
Nicola, N, et al.
Miller Glenn
Wallner Barbara P.
Point Therapeutics, Inc.
Russel Jeffrey Edwin
Wolf Greenfield & Sacks P.C.
LandOfFree
Anti-tumor agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-tumor agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tumor agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3433018